30 closest matches · ranked by relevance
Thrombocythemia, Hemorrhagic
Primary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time — 66.4; 66.9; 0.5; -1.1 percentage of ejection fraction
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
High Risk Polycythemia Vera · High Risk Essential Thrombocythemia
Primary: Number of Participants With Complete Remission (CR) — 17; 19; 12; 13 Participants
Essential Thrombocythemia (ET)
Primary: Percentage of Subjects Who Responded in Platelet Count — 67.9 percentage of subjects
Thrombocytopenia
Primary: Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study — 1; 6; 12; 9 Participants…
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Atherosclerosis
Primary: Carotid Artery Stiffness (Expressed by Beta-stiffness Index ) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From…
Acute Myeloid Leukemia · Essential Thrombocythemia
Primary: Recommended Phase 2 Dose of LY573636-Sodium in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Essential Thrombocythemia (ET)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Participants With a Platelet Response — 12; 0 Participants
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
Essential Thrombocythemia (ET)
Primary: Number of Participants Who Had One or More Adverse Events — 776 Participants
Essential Thrombocythemia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 73 Participants
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time to Platelet Count Response — 2.69; 2.88 days — p== 0.0099
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled Procedure — 22.9…
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure — 34.9; 68.6; 33.3; 87.9…
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 7; 1 Participants
Obscure Gastrointestinal Bleeding · Angiodysplasia · Gastric Antral Vascular Ectasia
Primary: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months — 20; 1 participants — p=0.00000013
Leukemia · Chronic Myelogenous Leukemia · Chronic Myeloid Leukemia
Primary: Number of Participants With Complete Response — 3 Participants
Idiopathic Thrombocytopenic Purpura
Primary: Weeks With Weekly Platelet Response — 0.0; 11.0 Weeks — p=<0.0001
Myeloproliferative Disorders
Primary: Number of Patients With Complete Response (CR) or Partial Response (PR) — 3; 3; 14; 23 Participants
Obstetric Labor Complications · Preeclampsia · Thrombocytopenia
Primary: Positive Predictive Value of Earliest Available Platelet Count — 99; 90; 100 percentage of positive platelet counts
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 — 1; 25 Participants…
Essential Thrombocythemia (ET)
Primary: Change From Baseline in Platelet Count at Final Assessment — 1021.6; -346.2 10^9 platelets per liter (10^9/L)
Extracorporeal Membrane Oxygenation Complication · Hemorrhage · Thromboembolism
Primary: Total Platelet Transfusion Dose — 7.4; 0 mL/kg/day
Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification — 84.4; 35.7 percentage of participants — p=< 0.001
Telangiectasia, Hereditary Hemorrhagic
Primary: Change From Baseline Epistaxis Severity Score — -1; -1.1; -1.3; -1.2 units on a scale